Baxter International and Halozyme Therapeutics have announced the launch of Hyqvia in the US, a subcutaneous immunoglobulin treatment for adult patients with primary immunodeficiency (PI).

Developed by Halozyme, Baxter’s Hyqvia product includes immune globulin infusion 10% (Human) (IG 10%) and recombinant human hyaluronidase.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

University of Texas Southwestern Medical School paediatrics clinical professor Richard Wasserman said: "Hyqvia will have a significant impact on the treatment of primary immunodeficiency."

The US Food and Drug Administration (FDA) approved Hyqvia in September.

Hyqvia is indicated for adult PI patients, which allows a full monthly dose of IG to be administered with only one injection site and one infusion each month.

"Hyqvia is for adult PI patients, allowing a full monthly dose of IG to be administered with one injection site and one infusion each month."

Baxter BioScience president Ludwig Hantson said: "With our swift commercial introduction, we look forward to sharing Hyqvia with adult PI patients seeking an option with less frequent dosing than current subcutaneous treatments without compromising efficacy, safety and tolerability.

"The goal of Hyqvia is to allow people with PI to feel less like patients by reducing the treatment burden associated with weekly dosing and multiple injection sites per dose."

In 2013, Hyqvia received European approval to treat adult patients with primary immunodeficiency syndromes and myeloma, or chronic lymphocytic leukemia (CLL) with severe secondary hypogammaglobulinemia and recurrent infections.

The treatment is currently available in European nations such as Germany, Netherlands, Sweden, Norway, Denmark, Ireland and Italy.

Image: Baxter International Inc. headquarters. Photo: courtesy of Tactweb.